An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).

Post time 1 hour(s) ago

revista: Revista de Oncología Clínica

Autores: Atul Sharma; Manish Kumar; Suman Bhasker; Alok Thakar; Raja Pramanik; Ahitagni Biswas; akash kumar; Kapil Sikka; Amit Chirom Singh; Supriya Mallick; Rajeev Kumar; SVS Deo; Aanchal Kakkar; Saphalta Baghmar; Amit Sehrawat; Pooja Sethi; Ashok Kumar; Sandeep Seth; Ashish Dutt Upadhyay; Sanjay Thulkar

Fecha de publicación: junio de 2022

DOI: 10.1200/jco.2022.40.16_suppl.6004

Enlace al PDF: https://ascopubs.org/doi/pdfdire ... 22.40.16_suppl.6004

Enlace al artículo: https://doi.org/10.1200/jco.2022.40.16_suppl.6004

Fuente del artículo: Sociedad Estadounidense de Oncología Clínica (ASCO) .

Observación:

[Other] An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial). Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).